Research Reports

Summary

Can-Fite BioPharma Ltd. reported its 2025 financial results and clinical updates, including a $9.83 million net loss, $0.41 million in revenues, and $6.69 million in R&D expenses. Clinical highlights include positive Phase 2a pancreatic cancer data, a 9-year cancer-free survival in an HCC patient on Namodenoson, and advancement of Namodenoson into Phase 3 for hepatocellular carcinoma and Phase 2b for MASH.

Key takeaways

Net loss for year ended December 31, 2025 was $9.83 million, up from $7.88 million in 2024.
Revenues for year ended December 31, 2025 were $0.41 million, down 40% from $0.67 million in 2024.
R&D expenses for year ended December 31, 2025 were $6.69 million, up 16.26% from $5.75 million in 2024.
Cash and cash equivalents plus short-term deposits totaled $8.54 million as of December 31, 2025, up from $7.88 million as of December 31, 2024.
A patient with advanced hepatocellular carcinoma treated with Namodenoson achieved over 9 years of cancer-free survival with complete response.
Namodenoson is in a Phase 3 study for hepatocellular carcinoma and a Phase 2b study for MASH, with Orphan Drug and Fast Track designations from the FDA.